MARCHESELLI, Luigi
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 15.857
EU - Europa 7.593
AS - Asia 6.402
SA - Sud America 749
OC - Oceania 518
AF - Africa 279
Continente sconosciuto - Info sul continente non disponibili 11
Totale 31.409
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 15.354
GB - Regno Unito 2.896
CN - Cina 1.526
SG - Singapore 1.145
IT - Italia 985
HK - Hong Kong 811
DE - Germania 779
SE - Svezia 618
BR - Brasile 596
PH - Filippine 525
AU - Australia 475
TR - Turchia 435
CA - Canada 396
RU - Federazione Russa 329
FR - Francia 313
IR - Iran 279
FI - Finlandia 272
UA - Ucraina 267
VN - Vietnam 206
IN - India 186
KR - Corea 179
PK - Pakistan 156
ID - Indonesia 142
IE - Irlanda 133
JP - Giappone 120
NL - Olanda 119
BG - Bulgaria 116
MY - Malesia 110
ES - Italia 99
GR - Grecia 97
PL - Polonia 96
TW - Taiwan 84
IL - Israele 75
ZA - Sudafrica 72
SA - Arabia Saudita 70
BE - Belgio 65
MA - Marocco 65
AT - Austria 58
MX - Messico 55
TH - Thailandia 51
AR - Argentina 43
LK - Sri Lanka 43
NP - Nepal 43
NZ - Nuova Zelanda 42
RO - Romania 40
GE - Georgia 39
NO - Norvegia 39
LT - Lituania 33
JO - Giordania 32
LV - Lettonia 32
CH - Svizzera 30
EC - Ecuador 30
KE - Kenya 30
EE - Estonia 28
CZ - Repubblica Ceca 27
BD - Bangladesh 25
PT - Portogallo 23
EG - Egitto 22
HR - Croazia 22
CO - Colombia 19
IQ - Iraq 18
NG - Nigeria 18
HU - Ungheria 17
SK - Slovacchia (Repubblica Slovacca) 17
CL - Cile 16
SI - Slovenia 15
BZ - Belize 14
PE - Perù 14
AE - Emirati Arabi Uniti 13
UG - Uganda 12
OM - Oman 10
UZ - Uzbekistan 10
DK - Danimarca 9
MU - Mauritius 9
TN - Tunisia 9
CY - Cipro 8
VE - Venezuela 8
LB - Libano 7
PR - Porto Rico 7
PY - Paraguay 7
A2 - ???statistics.table.value.countryCode.A2??? 6
BO - Bolivia 6
DZ - Algeria 6
ET - Etiopia 6
MO - Macao, regione amministrativa speciale della Cina 6
MV - Maldive 6
PA - Panama 6
BH - Bahrain 5
GY - Guiana 5
KZ - Kazakistan 5
LU - Lussemburgo 5
MW - Malawi 5
PS - Palestinian Territory 5
TT - Trinidad e Tobago 5
UY - Uruguay 5
CR - Costa Rica 4
DO - Repubblica Dominicana 4
EU - Europa 4
GH - Ghana 4
KG - Kirghizistan 4
Totale 31.337
Salva come PNG Salva come JPEG
Città #
Fairfield 1.815
Southend 1.619
Ashburn 1.363
Santa Clara 1.278
Woodbridge 1.142
Chandler 839
Houston 817
Hong Kong 726
Singapore 701
Seattle 684
Wilmington 652
Cambridge 590
Jacksonville 504
Dearborn 428
Ann Arbor 404
Nyköping 401
Hefei 370
London 331
Beijing 318
Modena 227
Los Angeles 196
Frankfurt am Main 190
New York 188
Redwood City 183
San Diego 178
Munich 173
Helsinki 161
Izmir 152
Chicago 139
Shanghai 118
Princeton 116
Sofia 113
Melbourne 104
Seoul 104
Council Bluffs 99
Eugene 96
Moscow 93
Jakarta 79
Dallas 76
Dublin 75
Milan 72
Manchester 69
Salt Lake City 66
Buffalo 64
Hanoi 62
Sydney 61
Bremen 59
Brisbane 59
Ho Chi Minh City 59
Istanbul 59
Ottawa 59
São Paulo 52
Bologna 49
Tokyo 49
Columbus 48
Falls Church 46
Taipei 46
Paris 44
Phoenix 44
Liverpool 43
Athens 42
The Dalles 41
Warsaw 40
Quezon City 38
Brussels 37
Des Moines 37
Fremont 37
Tehran 35
Casablanca 34
Dong Ket 34
Islamabad 34
Colombo 33
Perth 31
Elk Grove Village 30
Kuala Lumpur 30
Lahore 29
Manila 29
Toronto 29
Birmingham 28
Cebu City 28
Johannesburg 28
Karachi 28
Montreal 28
Norwalk 28
Riga 28
Riyadh 28
Tampa 28
Davao City 27
Rome 27
Vienna 27
Nanjing 26
San Jose 26
Greenwich 25
Bengaluru 24
Boardman 24
Boston 24
San Giuliano Milanese 24
Brooklyn 23
Guangzhou 23
Kathmandu 23
Totale 20.147
Salva come PNG Salva come JPEG
Nome #
Empathy and burnout: an analytic cross-sectional study among nurses and nursing students 6.602
R-CVP versus R-CHOP versus R-FM for the initial treatment of patients with advanced-stage follicular lmphoma: results of the FOLL05 trial conducted by the Fondazione Italiana Linfomi 601
Therapy-related myeloid neoplasm in non-hodgkin lymphoma survivors. 578
Long-Term Results of the FOLL05 Trial Comparing R-CVP Versus R-CHOP Versus R-FM for the Initial Treatment of Patients With Advanced-Stage Symptomatic Follicular Lymphoma 573
Absolute monocyte count at diagnosis could improve the prognostic role of early FDG-PET in classical Hodgkin lymphoma patients 427
ABVD Compared With BEACOPP Compared With CEC for the Initial Treatment of Patients With Advanced Hodgkin's Lymphoma: Results From the HD2000 Gruppo Italiano per lo Studio dei Linfomi Trial. 383
Anthracydine-fludarabine-containing regimens with or without rituximab in the treatment of patients with advanced follicular lymphoma 374
The impact of shift work on the psychological and physical health of nurses in a general hospital: a comparison between rotating night shifts and day shifts 357
N,N-DIMETHYLFORMAMIDE-2-METHOXYETHANOL SOLVENT SYSTEM - DENSITIES AND EXCESS MOLAR VOLUMES AT VARIOUS TEMPERATURES 350
Incidence, clinical characteristics and survival of malignant lymphomas: a population-based study from a cancer registry in northern Italy. 349
Secondary malignancies after treatment for indolent non-Hodgkin's lymphoma: A 16-year follow-up study 343
Second malignancies after treatment of diffuse large B-cell non-Hodgkin's lymphoma: a GISL cohort study 336
Defining the best cut-off value for lymphopenia in diffuse large B cell lymphoma treated with immuno-chemotherapy 318
A Multicenter Phase II Study of Twice-Weekly Bortezomib plus Rituximab in Patients with Relapsed Follicular Lymphoma: Long-Term Follow-Up 316
Incidence, clinical features and possible etiology of early onset (≤40 years) colorectal neoplasms. 312
Empathic attitudes among nursing students: a preliminary study 311
Safety and efficacy of lenalidomide in combination with rituximab in recurrent indolent non-follicular lymphoma: Final results of a phase II study conducted by the Fondazione Italiana Linfomi 311
Absolute monocyte count and lymphocyte-monocyte ratio predict outcome in nodular sclerosis Hodgkin lymphoma: Evaluation based on data from 1450 patients 307
Identification of protein clusters predictive of response to chemotherapy in breast cancer patients 304
The histone deacetylase inhibitor romidepsin synergizes with lenalidomide and enhances tumor cell death in T-cell lymphoma cell lines 303
Combination of low doses of Enzastaurin and Lenalidomide has synergistic activity in B-non-Hodgkin lymphoma cell lines 300
A multicenter retrospective clinical study of CD5/CD10-negative chronic B cell leukemias. 298
The outcome of peripheral t-cell lymphoma patients failing first-line therapy: A report from the prospective, international t-cell project 294
ABVD plus radiotherapy versus EVE plus radiotherapy in unfavorable stage IA and IIA Hodgkin's lymphoma: results from an Intergruppo Italiano Linfomi randomized study. 285
Prognostic relevance of serum beta2 microglobulin in patients with follicular lymphoma treated with anthracycline-containing regimens. A GISL study. 284
Ricolinostat, a selective HDAC6 inhibitor, shows anti-lymphoma cell activity alone and in combination with bendamustine 283
A NON-LINEAR CORRELATION MODEL FOR THE RELATIVE PERMITTIVITY OF TERNARY AMPHIPROTIC (SOLVENT) MIXTURES 276
Peripheral T cell lymphoma, not otherwise specified (PTCL-NOS). A new prognostic model developed by the International T cell Project Network 275
Follicular Lymphoma International Prognostic Index 2: a new prognostic index for follicular lymphoma developed by the International Follicular Lymphoma Prognostic Factor Project 273
Bendamustine, Low-dose dexamethasone, and lenalidomide (BdL) for the treatment of patients with relapsed/refractory multiple myeloma confirms very promising results in a phase I/II study 272
Long-term follow-up analysis of HD9601 trial comparing ABVD versus Stanford V versus MOPP/EBV/CAD in patients with newly diagnosed advanced-stage Hodgkin's lymphoma: a study from the Intergruppo Italiano Linfom 259
Neutrophil-lymphocyte ratio at diagnosis is an independent prognostic factor in patients with nodular sclerosis Hodgkin lymphoma: Results of a large multicenter study involving 990 patients 258
Risk for second malignancies in non-Hodgkin's lymphoma survivors: a meta-analysis 252
Prognostic models for diffuse large B-cell lymphoma in the rituximab era: a never-ending story. 252
Outcome of frail elderly patients with diffuse large B-cell lymphoma prospectively identified by Comprehensive Geriatric Assessment: Results from a study of the Fondazione Italiana Linfomi 252
Survival of multiple myeloma patients in the era of novel therapies confirms the improvement in patients younger than 75 years: a population-based analysis 252
Efficacy of bendamustine and rituximab in splenic marginal zone lymphoma: results from the phase II BRISMA/IELSG36 study 250
Risk of second primary malignancy in breast cancer survivors: A nested population-based case-control study 250
Tumor size, node status, grading, HER2 and estrogen receptor status still retain a strong value in patients with operable breast cancer diagnosed in recent years. 247
Prognostic value of PET-CT after first-line therapy in patients with follicular lymphoma: a pooled analysis of central scan review in three multicentre studies 245
Radiation therapy improves treatment outcome in patients with diffuse large B-cell lymphoma 244
Lymph node evaluation in stage IIA colorectal cancer and its impact on patient prognosis: A population-based study 244
NVP-BEZ235 alone and in combination in mantle cell lymphoma: an effective therapeutic strategy 244
Combined Hormonal Contraceptive Use and Risk of Breast Cancer in a Population of Women With a Family History 244
Cancer incidence, mortality, and survival in Eastern Libya: Updated report from the Benghazi Cancer Registry 241
A diachronic-comparative analysis for the identification of the most powerful prognostic index for localized diffuse large B-cell lymphoma 240
ANALYSIS OF HEAVY-METALS IN ACETO-BALSAMICO-TRADIZIONALE-DI-MODENA BY FLAME ATOMIC-ABSORPTION SPECTROSCOPY 237
Brca detection rate in an italian cohort of luminal early-onset and triple-negative breast cancer patients without family history: When biology overcomes genealogy 236
Reproductive risk factors in women with family history of breast cancer attending an Italian Family Cancer Clinic 235
Estimating survival in newly diagnosed cancer patients: use of computer simulations to evaluate performances of different approaches in a wide range of scenarios. 233
Rituximab and the risk of transformation of follicular lymphoma: a retrospective pooled analysis 233
Multicentre validation of an immune-inflammation-based nomogram to predict survival in western resectable gastroesophageal adenocarcinoma: The NOMOGAST 232
2-methoxyethanol - water solvent system : static relative permittivity from -10 to 80°C 229
Anthracycline-Fludarabine Containing Regimens with or without Rituximab in the Treatment of Advanced Follicular Lymphoma Patients 229
The combination of bortezomib with enzastaurin or lenalidomide enhances cytotoxicity in follicular and mantle cell lymphoma cell lines 229
Prognostic relevance of microsatellite instability in pT3N0M0 colon cancer: a population-based study 226
Rituximab with cyclophosphamide, vincristine, non-pegylated liposomal doxorubicin and prednisone as first-line treatment for splenic marginal zone lymphoma: a Fondazione Italiana Linfomi phase II study 225
Role of Glutathione-S-Transferase (GST) polymorphisms in patients with advanced Hodgkin Lymphoma: results from the HD2000 GISL Trial 225
The role of high-dose therapy and autologous stem cell transplantation in patients with primary refractory Hodgkin's lymphoma: a report from the Gruppo Italiano per lo Studio dei Linfomi (GISL) 224
Decreasing incidence of gastric MALT lymphomas in the era of anti-Helicobacter pilori interventions: results from a population-based study on extranodal marginal zone lymphomas 223
Cyclophosphamide, doxorubicin, vincristine, prednisone and rituximab versus epirubicin, cyclophosphamide, vinblastine, prednisone and rituximab for the initial treatment of elderly “fit” patients with diffuse large B-cell lymphoma: results from the ANZINTER3 trial of the Intergruppo Italiano Linfomi 223
Lifestyle intervention on body weight and physical activity in patients with breast cancer can reduce the risk of death in obese women: The EMILI study 222
Dielectric properties of ethane-1,2-diol + 2-methoxyethanol + water liquid ternary mixtures 217
Watchful waiting in low-tumorburden follicular lymphoma in the Rituximab era. Results of a F2 observational 216
The use of anthracycline at first-line compared to alkylating agents or nucleoside analogs improves the outcome of salvage treatments after relapse in follicular lymphoma The REFOLL study by the Fondazione Italiana Linfomi 216
A model for predicting the risk of developing mild anemia (MA) in patients with lymphoid malignancy. A study of the Gruppo Italiano Studio Linfomi (GISL) 214
Monocyte count at diagnosis is a prognostic parameter in diffuse large B-cell lymphoma: a large multicenter study involving 1191 patients, in the pre and post rituximab era 213
Introduction of rituximab in front-line and salvage therapies has improved outcome of advanced-stage follicular lymphoma patients 212
Long-term results of the HD2000 trial comparing ABVD versus BEACOPP versus COPP-EBV-CAD in untreated patients with advanced hodgkin lymphoma: A study by fondazione Italiana Linfomi 212
Incidence and clinicopathologic features of gastrointestinal stromal tumors. A population-based study. 211
Prognostic role of gender in diffuse large B-cell lymphoma treated with rituximab containing regimens: a Fondazione Italiana Linfomi/Grupo de Estudos em Moléstias Onco-Hematológicas retrospective study 211
Long term results of a randomized study performed by Intergruppo Italiano Linfomi comparing Mini-CEOP vs P-VEBEC in elderly patients with diffuse large B-cell lymphoma. 204
Minimal residual disease after conventional treatment significantly impacts on progression-free survival of patients with follicular lymphoma: The FIL FOLL05 trial 203
The impact of reproductive life on breast cancer risk in women with family history or BRCA mutation 202
The relative permittivity of the ternary 1,2-ethanediol + 2-methoxyethanol + water solvent system 201
Durability and efficacy of tibial arterial stent placement for critical limb ischemia 199
Prognostic roles of absolute monocyte and absolute lymphocyte counts in patients with advanced-stage follicular lymphoma in the rituximab era: an analysis from the FOLL05 trial of the Fondazione Italiana Linfomi 198
CLIPI: a new prognostic index for indolent cutaneos B cell lymphoma proposed by the International Extranodal Lymphoma Study Group (IELSG 11) 197
SECOND MALIGNANCIES AFTER TREATMENT FOR INDOLENT LYMPHOMA: A 16 YEARS FOLLOW-UP STUDY 191
Standard “off-the-shelf” multibranched thoracoabdominal endograft in urgent and elective patients with single and staged procedures in a multicenter experience 189
Second Malignancy After Treatment for Non-Hodgkin Lymphoma: a Systematic Review and a Meta-Analysis of Population-Based and Cohort Studies 185
Twenty-years experience with de novo metastatic breast cancer 182
VALIDATION OF ABSOLUTE LYMPHOCYTE COUNT / REVISED IPI (ALC/R-IPI) SCORE MODEL, AS A PROGNOSTIC INDEX FOR DIFFUSE LARGE-B-CELL LYMPHOMA IN RITUXIMAB ERA 179
Early-stage diffuse large B cell lymphoma of the head and neck: clinico-biological characterization and 18 year follow-up of 488 patients (IELSG 23 study) 178
I tumori nelle provincie di Parma, Reggio Emilia, Modena 173
BRCA mutations among triple negative breast cancer without family history of breast and ovarian cancer: The Modena family cancer clinic experience 173
Citarinostat and Momelotinib co-target HDAC6 and JAK2/STAT3 in lymphoid malignant cell lines: a potential new therapeutic combination 171
Introduction of Combined Chemotherapies Plus Rituximab (R) Has Improved Outcome of Previously Untreated and Relapsed Follicular Lymphoma (FL) Patients (pts).. 170
Response-guided ABVD chemotherapy plus involved-field radiation therapy for intermediate-stage Hodgkin lymphoma in the pre-positron emission tomography era: a Gruppo Italiano Studio Linfomi (GISL) prospective trial. 170
Phase II Fludarabine and Cyclophosphamide for the treatment of indolent cell non-follicular lymphomas: final results of the LL02 trial of the Gruppo Italiano per lo Studio dei Linfomi. 169
Improving the international prognostic index score using peripheral blood counts: Results of a large multicenter study involving 520 patients with diffuse large B cell lymphoma 167
The A.L.A.N. score identifies prognostic classes in advanced biliary cancer patients receiving first-line chemotherapy 164
Treatment of patients with recurrent follicular lymphoma with rituximab in combination with fludarabine and cyclophosphamide 163
The Relative Permittivity of N,N-Dimethylformamide/1,2-Dimethoxyethane Binary Mixtures from -10 to 40 C 159
Contemporary economic and clinical evaluations of endovascular repair for intact descending thoracic aortic aneurysms 159
Long-term results of the MCL01 phase II trial of rituximab plus HyperCVAD alternating with high-dose cytarabine and methotrexate for the initial treatment of patients with mantle cell lymphoma 146
Rituximab in combination with chemotherapy has improved survival of patients with follicular lymphoma 144
A Fondazione Italiana Linfomi cohort study of R-COMP vs R-CHOP in older patients with diffuse large B-cell lymphoma 135
Influence of Thoracic Endovascular Repair on Aortic Morphology in Patients Treated for Blunt Traumatic Aortic Injuries: Long Term Outcomes in a Multicentre Study 133
Incidence and outcomes of rare T cell lymphomas from the T Cell Project: hepatosplenic, enteropathy associated and peripheral gamma delta T cell lymphomas 133
Totale 31.189
Salva come PNG Salva come JPEG
Categoria #
all - tutte 107.629
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 107.629
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20212.977 0 0 0 0 515 373 284 439 293 452 371 250
2021/20223.136 194 240 388 194 143 218 170 207 338 260 489 295
2022/20233.279 285 357 233 328 359 401 144 304 390 151 180 147
2023/20243.220 111 149 218 250 622 263 469 377 110 180 218 253
2024/20255.924 195 113 193 476 1.102 779 476 436 680 269 502 703
2025/20263.399 658 424 690 1.193 434 0 0 0 0 0 0 0
Totale 31.821